Hundae Aneley, Afzal Aasim, Assar Manish D, Schussler Jeffrey M
Department of Internal Medicine (Hundae), Division of Cardiology (Afzal, Schussler), Baylor University Medical Center at Dallas; and the Department of Internal Medicine, Texas A&M College of Medicine (Schussler).
Proc (Bayl Univ Med Cent). 2014 Oct;27(4):325-6. doi: 10.1080/08998280.2014.11929146.
Donepezil, an acetylcholinesterase inhibitor, is approved for the treatment of mild to moderate dementia secondary to Alzheimer's disease. Although most prescribers are aware of the common gastrointestinal side effects of donepezil, cardiovascular side effects are rarely observed. Cardiovascular side effects of donepezil have almost always been observed in patients with a history of conduction defects or sick sinus syndrome. We report a case of a woman with early onset Alzheimer's disease and no history of cardiac disease who developed second-degree heart block after a few weeks of therapy with donepezil. Withdrawal of donepezil led to resolution of the atrioventricular block.
多奈哌齐是一种乙酰胆碱酯酶抑制剂,已被批准用于治疗阿尔茨海默病所致的轻至中度痴呆。尽管大多数开处方者都知道多奈哌齐常见的胃肠道副作用,但心血管副作用很少见。多奈哌齐的心血管副作用几乎总是在有传导缺陷或病态窦房结综合征病史的患者中观察到。我们报告一例早发性阿尔茨海默病且无心脏病史的女性患者,在使用多奈哌齐治疗几周后出现二度心脏传导阻滞。停用多奈哌齐后房室传导阻滞得到缓解。